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Abstract
Background: Mechanisms underlying the inverse association between physical activity and survival after breast
cancer are unresolved, but DNA methylation may play a role. We hypothesized that promoter methylation of breast
cancer-related genes, as well as global methylation, may modify the association between prediagnostic recreational
physical activity (RPA) and breast cancer mortality.
Methods: Using a population-based sample of 1254 women diagnosed with first primary breast cancer, we
examined modification of the RPA-mortality association by gene-specific promoter methylation and global
methylation. Average lifetime RPA was assessed from menarche to diagnosis through structured in-home
interviews. Promoter methylation of 13 breast cancer-related genes was evaluated in archived tumor by
methylation-specific polymerase chain reaction and MethyLight assay. Global methylation in white blood cell
DNA was determined at long interspersed nucleotide element 1 and by the luminometric methylation assay.
After approximately 15 years of follow-up, 486 patients had died, and 186 of the deaths were breast cancer-related.
We used Cox proportional hazards regression to estimate HRs and 95% CIs as well as likelihood ratio tests to assess
multiplicative interactions.
Results: All-cause mortality was lower only among physically active women with methylated promoter of APC
(HR 0.60, 95% CI 0.40–0.80), CCND2 (HR 0.56, 95% CI 0.32–0.99), HIN (HR 0.55, 95% CI 0.38–0.80), and TWIST1
(HR 0.28, 95% CI 0.14–0.56) in tumors, but not among those with unmethylated tumors (significant interaction p < 0.05).
We found no interaction between RPA and global methylation.
Conclusions: The improved survival after breast cancer that is associated with RPA may be more pronounced in
women with promoter tumor methylation in biologically plausible genes.
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Background
With an estimated 40,000 deaths in 2017, breast cancer
is the second leading cause of cancer-related death in
the United States [1]. Women who engage in physical
activity prior to the diagnosis of breast cancer have bet-
ter overall survival than those who do not [2], but the
mechanisms of this association are unknown. Given that
only 20% of the U.S. population achieves the Centers for
Disease Control and Prevention’s physical activity guide-
lines [3], improved understanding of how physical activ-
ity influences breast cancer prognosis could have
significant public health impact.
Epigenetics is the study of functionally relevant changes
to the genome that do not involve a change in the nucleo-
tide sequence. DNA methylation is the most extensively
studied epigenetic modification and involves the addition
or removal of methyl (-CH3) groups at CpG dinucleotides
that influence gene regulation [4]. DNA methylation can
be measured in a range of tissues, including tumor and
blood [5], and has been associated with breast cancer
prognosis in several studies, including our own [6, 7].
Although methylation signatures are largely established
during embryogenesis [8], DNA methylation (and other
features of the epigenome) may be modified throughout
the life course as a result of both behavioral and environ-
mental stimuli [9], including physical activity [10]. Interac-
tions between the environment and DNA methylation
may, therefore, inform prognostic outcomes among
women diagnosed with breast cancer.
In a population-based sample of women diagnosed
with first primary breast cancer, we aimed to understand
whether the association between prediagnostic recre-
ational physical activity (RPA) and all-cause or breast
cancer-specific mortality was modified by gene promoter
methylation (which regulates gene expression) in a panel
of 13 breast cancer-related genes (APC, BRCA1, CCND2,
CDH1, DAPK1, ESR1, GSTP1, HIN1, CDKN2A, PGR,
RARβ, RASSF1A, and TWIST1) measured in tumor
tissue. Similarly, we sought to determine whether the
RPA-mortality association was modified by global DNA
methylation (a marker of genome stability) using two
methods to assess white blood cell methylation: long
interspersed nucleotide element 1 (LINE-1), which ap-
proximates levels in repetitive elements [11], and the
luminometric methylation assay (LUMA), which esti-
mates methylation at CCGG sites [12]. We hypothesized
that methylation of oncogenes (or lack of methylation in
tumor suppressor genes) and high prediagnostic physical
activity engagement would result in lower all-cause and
breast cancer-specific mortality among women diag-
nosed with first primary breast cancer. We also hypothe-
sized that physical activity and low LUMA (high LINE-
1) would work in synergy to reduce mortality following
a breast cancer diagnosis.
Methods
For this project, we used resources from the follow-up
component of the Long Island Breast Cancer Study Pro-
ject (LIBCSP), a population-based study. Details of the
study design and participants for this component have
been described previously [13, 14].
Study participants
Eligible participants in the LIBCSP follow-up study were
English-speaking female residents of Nassau and Suffolk
counties on Long Island, NY, USA, who were newly diag-
nosed with a first primary in situ or invasive breast cancer
between 1 August 1996 and 31 July 1997. Potentially
eligible subjects were identified through daily or weekly
contact with pathology departments of all 28 hospitals on
Long Island and 3 tertiary care hospitals in New York
City. At diagnosis, the 1508 women with breast cancer
were aged 20–98 years, predominately postmenopausal
(67%) and white (94%), which is consistent with the
underlying racial/ethnic distribution in these two New
York counties at the time of data collection.
Data collection
Recreational physical activity and other covariates
Approximately 2–3 months after diagnosis, women were
interviewed at home by trained interviewers using struc-
tured questionnaires. As part of this baseline (on average
100-minute) interview, RPA was assessed using a modified
instrument developed by Bernstein and colleagues for epi-
demiologic studies of breast cancer [15]. RPA from me-
narche to diagnosis was used to estimate lifetime RPA,
and women were classified as inactive, low RPA (<6.36 h/
week), and high RPA (≥6.36 h/week) on the basis of the
median for the entire cohort as previously described [16].
During the baseline interview, participants were addition-
ally queried on their demographic characteristics (includ-
ing age, race/ethnicity, income, and education), lifestyle
characteristics (including cigarette smoking and body
size), medical histories (including family history of breast
cancer, exogenous hormone use, and mammography
screening), and other breast cancer-related factors as pre-
viously described [13, 14].
Medical records data
Medical records were abstracted at baseline and again
approximately 5 years later to determine tumor charac-
teristics (e.g., estrogen receptor [ER]/progesterone recep-
tor [PR] status, tumor size, and nodal involvement) as
well as the first course of treatment for the first primary
breast cancer diagnosis.
Gene-specific promoter methylation
DNA extraction from archived formalin-fixed, paraffin-
embedded tumor tissue of the first primary breast cancer
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was performed as previously described [17]. Among the
975 women with archived tumor tissue, 807 (82.8%) had
available gene promoter methylation data. The 807
women with tumor methylation data did not differ from
the 1508 eligible women on most demographic and clin-
ical characteristics. Women with tumor methylation data
were more likely to have nodal involvement and invasive
cancer (data not shown), which reflects the amount of
tumor material available for methylation analyses.
Thirteen genes known to be involved in breast
carcinogenesis, and frequently methylated in promoter
regions, were selected for assessing interactions with
RPA. Promoter methylation of ESR1, PR, and BRCA1 was
determined by methylation-specific (MSP) polymerase chain
reaction (PCR) and was dichotomized (i.e., methylated vs.
unmethylated) on the basis of the presence or absence of
the PCR band [17, 18]. The methylation status of the ten
remaining genes was assessed by the MethyLight assay (Qia-
gen, Valencia, CA, USA) [19, 20]. The percentage of methy-
lation was calculated by the comparative cycle threshold (2
−ΔΔCT) method, where ΔΔCT = (CT,Target −CT,Actin)sample
− (CT,Target −CT,Actin)fully methylated DNA [21], and multiplying
by 100. Using a 4% cutoff, we dichotomized into methylated
or unmethylated cases as previously reported [22].
Global methylation
For 1102 (73.1%) of women with breast cancer, trained
phlebotomists obtained a nonfasting 40-ml blood sample
at the baseline interview, and DNA was isolated as
previously described [23]. Details of LUMA and LINE-1
assessment in the LIBCSP have been detailed previously
[12]. Briefly, LUMA was carried out according to the
modified protocol described by Bjornsson et al. [24] and
was expressed as a percentage based on the following
equation: methylation (%) = [1 − (HpaII ΣG/ΣT)/(MspI
ΣG/ΣT)] × 100 [24]. Four CpG sites in the promoter
region of LINE-1 were assessed using a prevalidated
pyrosequencing-based methylation assay [19] and were
individually analyzed as a T/C single-nucleotide poly-
morphism using Q-CpG software (Qiagen). These data
were subsequently averaged to provide an overall per-
centage 5-methylcytosine status.
Mortality
We used the National Death Index to determine vital status
through the end of 2011 as previously reported [25]. After
approximately 14.7 (0.2–15.4) years of follow-up, among the
1254 patients with any gene-specific (range n= 726–803
women with gene promoter methylation status) or global
methylation (range n = 1005–1015 women with LUMA or
LINE-1) assessments and complete RPA data, we identified
421 who died as a result of any cause, of which 186 deaths
were breast cancer-related (determined using International
Classification of Diseases code 174.9 or C-50.9).
Statistical analysis
We used Cox proportional hazards regression [26] to es-
timate HRs and 95% CIs for the association between
RPA, methylation status (global and gene-specific), and
mortality (all-cause and breast cancer-specific) among
1254 women with any methylation biomarker and
complete RPA assessment. The 1254 women with breast
cancer did not meaningfully differ from the original
1508 who were eligible. The women were more likely to
have nodal involvement and invasive cancer, which relate
to the amount of tumor material that would be available
for assay. All statistical tests were two-sided (a priori sig-
nificance level of 0.05). The proportional hazards as-
sumption was assessed using exposure interactions with
log-time [26]. We observed no violations of the propor-
tional hazards assumption with the 13 breast-cancer re-
lated genes, global methylation markers, or RPA.
For interaction analyses, we assessed RPA using a three-
level classification based on the median level among active
participants: inactive, low RPA (<6.36 h/week), and high
RPA (≥6.36 h/week). As detailed above, methylation of
gene promoters was classified as methylated or unmethy-
lated using a 4% cutoff, and global methylation markers
(LUMA and LINE-1) were dichotomized at the median.
Effect measure modification on the multiplicative scale be-
tween RPA and methylation was evaluated using the likeli-
hood ratio test with a 0.05 significance level [27].
All models were initially adjusted for age at diagnosis.
We further considered inclusion of family history of
breast cancer (yes/no), history of benign breast disease
(yes/no), cigarette smoking (ever/never), race (white,
black, other), and body mass index (BMI; <25.0 kg/m2,
25.0–29.9 kg/m2, ≥30 kg/m2). Covariates were removed
from the multivariate model using backward elimination.
Variables remained in the final model if their exclusion
changed the effect estimate by >10% [28]. None of these
covariates met our criteria, and thus all models were ad-
justed for age at diagnosis only.
When constructing our models, we did not consider
tumor characteristics (e.g., tumor stage, grade, size, and
nodal involvement) or hormone receptor status as poten-
tial confounders of the association between RPA, methyla-
tion, and mortality. These covariates are on the causal
pathway between prediagnostic RPA and mortality, and
adjustment for a causal intermediate would result in
biased parametric estimates [29, 30]. Although our study
population includes women with invasive (84%) and in
situ (16%) breast cancer, our findings restricted to invasive
tumors did not vary substantially from those among all
women, likely owing to the lower proportion of in situ
cases in our study population. We therefore considered
both invasive and noninvasive cases in these analyses. All
statistical analyses were performed using SAS statistical
software version 9.4 (SAS Institute, Cary, NC, USA).
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Results
Distribution of clinical characteristics
The distribution of clinical characteristics by RPA category
among the 1254 women with breast cancer included in
this study are provided in Table 1. The distribution of clin-
ical characteristics by outcome (all-cause and breast
cancer-specific mortality) is available in Additional file 1:
Table S1. Women who engaged in RPA across the life
course tended to have younger age at diagnosis and a
lower BMI, and they were slightly less likely to have nodal
involvement. We found little difference in other clinical
characteristics (i.e., ER or PR status) among physically ac-
tive women compared with inactive women.
Associations between RPA and all-cause and breast
cancer-specific mortality
In Table 2, we provide effect estimates for the associ-
ation between prediagnostic lifetime RPA and mortality
after approximately 15 years of follow-up among our
LIBCSP cohort of 1254 women newly diagnosed with
first primary breast cancer in 1996–1997. The associ-
ation between lifetime RPA and mortality among the en-
tire cohort of 1508 women with breast cancer with
follow-up through 2002 was previously reported [14];
follow-up has now been updated and extended through
2011. Our updated estimates showing inverse associa-
tions with both all-cause and breast cancer-specific mor-
ality are similar to the earlier reported estimates in the
LIBCSP based on 5 years of follow-up. The biological
relevance and function of the 13 genes investigated in
this study [31] are summarized in Additional file 2: Table
S2, along with previously reported associations with RPA
[32] and breast cancer-specific mortality [33].
Associations between RPA, DNA methylation, and
mortality
As shown in Table 3, the association between prediagnostic
lifetime RPA and all-cause mortality following a breast can-
cer diagnosis was lower among active women (>6.36 h/
week of RPA) with breast tumor promoter methylation in
APC (HR 0.60, 95% CI 0.40–0.80), CCND2 (HR 0.56, 95%
CI 0.32–0.99), HIN (HR 0.55, 95% CI 0.38–0.80), and
TWIST1 (HR 0.28, 95% CI 0.14–0.56), but not among ac-
tive women with unmethylated tumors (p < 0.05 for multi-
plicative interaction). Overall, we found substantially lower
risk of all-cause mortality among women with any RPA and
methylated gene promoters than among active women with
unmethylated promoters (Fig. 1). For example, we observed
an almost 50% lower risk of death as a result of all causes
among very active women with methylated HIN1 promoter
(HR 0.55, 95% CI 0.38–0.80). In contrast, there was no cor-
responding risk reduction for RPA among those with
unmethylated HIN1 promoter (HR 1.09, 95% CI 0.61–
1.81). We observed similar patterns of association for breast
cancer-specific mortality, albeit the interaction was not sig-
nificant (RPA HR 0.96, 95% CI 0.40–2.29 for unmethylated
HIN1 vs. RPA HR 0.52, 95% CI 0.30–0.90 for unmethylated
HIN1; multiplicative interaction p = 0.066). We did not ob-
serve an interaction between RPA, APC methylation, and
breast cancer-specific mortality (p = 0.138). For CCND2
and TWIST1, we were unable to evaluate effect modifica-
tion owing to small cells.
When we restricted our analyses to women with hor-
mone receptor-positive breast cancer only (defined as
any ER- or PR-positive), our estimates became less pre-
cise but were similar in effect size, and most interactions
persisted (Additional file 3: Table S3). The association
between RPA and mortality among women with breast
cancer was not modified by global methylation markers,
LINE-1, or LUMA (Additional file 4: Table S4).
Discussion
In this population-based follow-up study of 1254 women
diagnosed with first primary breast cancer, we found that
the overall improved survival among women with any
lifetime prediagnostic RPA appeared to be modified by
gene-specific methylation profiles. We observed substan-
tially improved survival with high lifetime prediagnostic
RPA in women with a tumor-methylated APC, CCND2,
HIN1, or TWIST1 gene promoter compared with active
women with unmethylated gene promoters. A more pro-
nounced risk reduction was observed for breast cancer-
specific mortality for the interaction with HIN1; how-
ever, we were unable to evaluate interactions with breast
cancer-specific mortality owing to small numbers. We
found no interaction between RPA and global methyla-
tion as measured by LINE-1 and LUMA. Our findings
suggest that the inverse association between RPA and
mortality after breast cancer may depend upon gene-
specific methylation profiles.
Improved survival with RPA among women with breast
cancer has been observed in many epidemiologic studies
[2], including our own [14]. Also, we [6] and others have
reported associations between gene-specific methylation
and prognosis [34]. However, to our knowledge, no previ-
ous investigation has considered gene methylation as a po-
tential modifier of the RPA-mortality association, despite
strong biologic plausibility. Not only does physical activity
reduce adiposity and its numerous metabolic correlates,
but it is itself thought to reduce markers of inflammation,
alter immune functioning, and lower circulating insulin
[35, 36]. These pathways have been linked to aberrant
DNA methylation, altering several genes implicated in
breast carcinogenesis [37–40]. Collectively, these data sug-
gest that the mechanisms underlying the inverse associ-
ation between RPA and mortality may be facilitated and/
or altered by inflammation-related methylation changes.
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In the present study, we found that the improved sur-
vival after breast cancer with high RPA was greatest
among patients with methylated APC, CCND2, HIN1,
and TWIST1 promoters. APC and HIN1 are candidate
tumor suppressors thought to be involved in breast car-
cinogenesis [41, 42]. Our observation of decreased mor-
tality among very active women with APC or HIN1
methylation is counter to our a priori hypothesis of low-
ered risk of death among active women with unmethy-
lated (active) tumor suppressor genes, although we did
observe that in the highest RPA group, there was no
statistical difference in the effect among APC methylated
and unmethylated cases. We observed risk reductions at
both low and high RPA engagement among women with
methylated HIN1 promoters. Methylation of HIN1 is
linked to gene silencing, reduced expression, and loss of
apoptosis [43]. HIN1 is a putative growth inhibitory
cytokine thought to be inactivated at the earliest stages
of breast tumorigenesis and silenced in the majority of
sporadic breast carcinomas [44]. This may suggest that
prediagnostic RPA could help overcome the deleterious
effects of HIN1 inactivation in breast carcinogenesis,
thereby improving survival outcomes.
The exact roles of CCND2 and TWIST1 in breast cancer
are unresolved. CCND2 is important in cell cycle regulation
Table 1 Distribution of clinical characteristics by recreational
physical activity category among the 1254 participants with any
information on methylation (gene-specific and/or global) and
lifetime physical activity in a population-based cohort of women
diagnosed with first primary breast cancer, Long Island Breast
Cancer Study Project
Recreational
physical activity
Inactive
(n = 294)
<6.36 h/week
(n = 497)
≥6.36 h/week
(n = 463)
n (%) n (%) n (%)
Age at diagnosis
<50 years 55 (18.71) 170 (34.21) 136 (29.37)
≥50 years 239 (81.29) 327 (65.79) 327 (70.63)
Menopausal status
Premenopausal 55 (19.37) 187 (38.09) 148 (32.74)
Postmenopausal 229 (80.63) 304 (61.91) 304 (67.26)
Family history of breast cancer
No 225 (78.13) 396 (82.16) 361 (80.94)
Yes 63 (21.88) 86 (17.84) 85 (19.06)
Body mass index (BMI)
BMI <25 kg/m2 113 (38.97) 240 (48.58) 200 (43.67)
BMI 25–29.9 kg/m2 92 (31.72) 157 (31.78) 157 (34.28)
BMI ≥30 kg/m2 85 (29.31) 97 (19.64) 191 (22.05)
Cigarette smoking
Never 138 (46.94) 231 (46.48) 199 (42.98)
Current/former 156 (53.06) 266 (53.32) 264 (57.02)
History of benign breast disease
No 248 (84.35) 393 (79.07) 370 (80.09)
Yes 46 (15.65) 104 (20.93) 92 (19.91)
Cancer type
In situ 39 (13.27) 97 (19.52) 57 (12.31)
Invasive 255 (86.73) 400 (80.48) 406 (87.69)
Hormone receptor statusa
Positive 158 (81.44) 252 (78.02) 260 (79.75)
Negative 36 (18.35) 71 (21.98) 66 (20.25)
Estrogen receptor status
Positive 147 (75.77) 235 (72.76) 248 (76.07)
Negative 47 (24.23) 88 (27.24) 78 (23.93)
Progesterone receptor status
Positive 125 (64.43) 203 (62.85) 220 (67.48)
Negative 69 (35.57) 120 (37.15) 106 (32.52)
Tumor size
<2 cm 94 (60.26) 171 (66.28) 187 (68.75)
≥2 cm 62 (39.74) 87 (33.72) 85 (31.25)
Nodal involvement
0 45 (27.78) 73 (27.76) 48 (18.05)
1 117 (72.22) 190 (72.24) 218 (81.95)
Treatment type
No chemotherapy 120 (65.57) 206 (56.59) 183 (60.00)
Table 1 Distribution of clinical characteristics by recreational
physical activity category among the 1254 participants with any
information on methylation (gene-specific and/or global) and
lifetime physical activity in a population-based cohort of women
diagnosed with first primary breast cancer, Long Island Breast
Cancer Study Project (Continued)
Chemotherapy 63 (34.43) 158 (43.41) 122 (40.00)
No radiation 75 (40.98) 148 (40.55) 113 (36.81)
Radiation 108 (59.02) 217 (59.45) 194 (63.19)
No hormone therapy 58 (32.22) 144 (40.11) 119 (39.40)
Hormone therapy 122 (67.78) 215 (59.89) 183 (60.60)
a Any estrogen receptor-positive or progesterone receptor-positive tumor
Table 2 Age-adjusted HRs and 95% CIs for the association
between lifetime recreational physical activity and 15-year all-cause
and breast cancer-specific mortality among a population-based
sample of 1254 women with a first primary breast cancer,
Long Island Breast Cancer Study Project
All-cause mortality Breast cancer-specific
mortality
Recreational physical activitya
Inactive 129/294 1.00 Reference 55/294 1.00 Reference
<6.36 h/week 144/497 0.71 (0.56–0.90) 66/497 0.60 (0.42–0.86)
≥ 6.36 h/week 148/463 0.75 (0.59–0.94) 65/463 0.66 (0.46–0.95)
aCleveland et al. [14] previously reported age-, BMI-, and menopausal status-
adjusted associations for prediagnostic recreational physical activity (measured
as metabolic equivalents of task-h/week), with follow-up though 2002
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and has been cited as both a tumor suppressor gene [45]
and an oncogene [46]. Inactivation of CCND2 is thought to
occur via promoter hypermethylation, which may be an
early, though infrequent (about 11%), event in malignant
breast cancer transformation [45, 47, 48]. In our study, we
found lower all-cause mortality among women with pro-
moter methylation (or loss of CCND2 expression) in tumor
tissue. This may reflect synergy between physical exercise
and inactivation of the CCND2 oncogene, particularly
among women with low RPA. TWIST1 is an antiapoptotic
and prometastatic transcription factor, and methylation of
the gene promoter has been observed frequently in malig-
nant breast tissue [49]. We observed pronounced reduc-
tions in all-cause mortality among physically active patients
with TWIST1 methylation, which is consistent with our a
priori hypothesis of synergy between the presumptive onco-
gene and RPA.
Although our population-based study of women with
breast cancer was carefully conducted and included com-
prehensive exposure assessment and a long follow-up
time, several potential limitations should be considered.
First, information on RPA was collected systematically by
trained interviewers [13]; nonetheless, there is potential
for nondifferential measurement error, which would result
in reduced effect estimates. However, LIBCSP investiga-
tors used a comprehensive, open-ended approach to query
women on their lifetime RPA habits. This approach has
been shown to elucidate important relationships between
RPA and breast cancer in the LIBCSP [14, 16] and is con-
sistent with other findings [50]. Second, postdiagnostic
RPA, which likely influences prognosis [51], was not con-
sidered in this investigation, owing to small cells after
stratification by methylation status. Third, we were limited
to a panel of 13 biologically relevant genes and 2 global as-
says. However, studies employing more robust panels that
interrogate hundreds of thousands of CpG sites are at high
risk for false-positives, generally lack biologically driven
hypotheses, and perform modestly using archived tumor
samples [52, 53]. Additionally, we were limited by the use
of conventional MSP PCR assays for three of the genes.
However, where quantitative MSP PCR assays have the
advantage of providing a quantitative estimate of methyla-
tion, the conventional MSP assay is a highly sensitive
method to classify individuals by methylation status,
which mitigates the threat of biased results [54, 55].
Finally, the racial homogeneity of our study population re-
stricted our ability to explore potential variation by intrin-
sic subtype or by race, both of which are known to
associate with prognostic outcomes [56]. Nonetheless, the
largest hormonal subtype of breast cancer diagnosed
among U.S. women of any race is ER+PR+ [57], which
continues to increase with time [58] and is the predomin-
ant subtype of breast cancer diagnosed among LIBCSP
study participants. When we restricted our findings to
women with only hormone-responsive breast tumors, re-
sults were similar to those for all women.
Fig. 1 Age-adjusted HRs and 95% CIs for the association between lifetime recreational physical activity (RPA) and 15-year all-cause and breast
cancer-specific mortality, stratified by gene methylation status (methylated vs. unmethylated tumors), among 803 women diagnosed with a first
primary breast cancer and with available gene promoter methylation data, Long Island Breast Cancer Study Project. Closed circles = low RPA
(<6.36 h/week). Open circles = high RPA (≥6.36 h/week). Compared with inactive women (data point not shown, HR 1.0)
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Conclusions
To our knowledge, we are the first to show, using resources
from a population-based follow-up study, that promoter
methylation of APC, CCND2, HIN1, and TWIST1 may
modify the inverse association between prediagnostic RPA
and all-cause mortality following a breast cancer diagnosis.
With the exception of HIN1, which was suggestive of breast
cancer-specific mortality, power was limited for examining
potential modification of the association between RPA and
breast cancer-specific mortality. Although our results re-
quire confirmation in cohort studies with a larger number
of women with breast cancer and more comprehensive
gene coverage, they suggest that DNA methylation may play
an important role in associations between physical activity
and improved survival among women with breast cancer.
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